Latest Breaking News On - Peter maccallum cancer centre - Page 1 : vimarsana.com

Pfizer's LORBRENA Study: Majority ALK+ Lung Cancer Patients Live Five Years Disease-Free

Calls to build palliative care capacity in regional areas ahead of expected rise in demand

Jeremy Adlam is receiving palliative care on his mum's farm, but organising it proved difficult. Experts say it's a problem that needs to be addressed now.

ctDNA Analysis Not Enough to Guide Treatment Decisions in Early Pancreatic Cancer

Adjuvant chemo de-escalation based on ctDNA had no effect on recurrence-free survival

'Outstanding' 5 Year PFS With Lorlatinib in ALK+ NSCLC

Five-year follow-up data from the landmark CROWN trial shows significant progression-free survival in ALK+ NCSLC, but some experts question the use of crizotinib as the comparator drug.

Lung cancer treatment: Pfizer's Lorbrena extends life in some non-small cell lung cancers

Pfizer's LORBRENA® CROWN Study Shows Majority of Patients with ALK-Positive Advanced Lung Cancer Living Beyond Five Years Without Disease Progression

An unprecedented 60% of patients remain alive without disease progression after five years Updated results show continued 81% reduction in risk of progression or death and 94% reduction in...

Trial results for new lung cancer drug are 'off the charts', say doctors | Lung cancer

More than half of patients with advanced forms of disease who took lorlatinib were still alive after five years with no progression

New lung cancer pill could 'stop disease in its tracks'

Unprecedented PFS Results in ALK-Positive Lung Cancer Trial

Lung cancer wonder drug hailed as study shows 'off the chart' survival benefit